Medicare AdvantageCoverageMedium impact
Genetic and Protein Biomarkers for the Diagnosis and Cancer Risk Assessment of Prostate Cancer
Blue Cross Blue Shield of Rhode Island·RI · Urology, Oncology·Physician / Facility
Effective date
May 1, 2022
We identified it
Jun 19, 2026
Summary
BCBS Rhode Island is updating medical necessity criteria for ExoDx Prostate IntelliScore (EPI) testing for Medicare Advantage plans effective May 1, 2022. The policy affects genetic and protein biomarker testing used for prostate cancer diagnosis and risk assessment.
Action Required
Review the updated draft medical policy at the provided URL to understand new medical necessity criteria for ExoDx Prostate IntelliScore (EPI) testing. Update prior authorization and documentation requirements for Medicare Advantage patients receiving this genetic biomarker testing for prostate cancer assessment.